Results of Genome-Wide Association Study in Quebec Founder Population
published in Proceedings of the National Academy of Sciences (PNAS)
MONTREAL, September 5 /CNW/ - Genizon BioSciences today announced
publication in this week's Proceedings of the National Academy of Sciences of
four novel loci in Crohn's disease, in addition to confirmation of three known
Crohn's disease genes. These discoveries are derived from a genome-wide
association study in the Quebec Founder Population, which provides a unique
advantage for comprehensive discovery of disease genes in complex disorders.
The new discoveries are expected to lead to the development of novel and more
effective treatments for this disease.
Crohn's disease is an inflammatory bowel disorder with a strong genetic
component. Diet and environment are also contributing factors. These complex
origins have made it difficult for scientists to pinpoint the best targets for
"These discoveries were made in 2004 when we conducted the world's first
comprehensive genome-wide association study for a common disease," commented
Dr. John Hooper, CEO of Genizon.
"We have done a great deal of research and analysis since then,
culminating in this publication and also leading to a comprehensive "GeneMap"
of gene-gene interactions and biochemical pathways. We believe Genizon is the
first organization to identify a large number of interacting genes that are
linked to the root cause of a common disease."
The discoveries featured in the PNAS publication were replicated and
refined in two German populations, demonstrating the applicability of findings
in the Quebec Founder Population to general patient populations. The study
includes large scale sequencing and maps explaining how the multiple
susceptibility loci interact to result in disease.
"We were able to take Genizon's gene discoveries forward and add specific
disease knowledge to these discoveries and gene-gene interactions," said
Genizon's German collaborator, Professor Stefan Schreiber, Director of the
Institute for Clinical Molecular Biology at the University Hospital
Schleswig-Holstein. "These discoveries provide new and exciting information on
how tissue repair, epithelial defence and immune response may be targeted
producing more effective therapies. They open the door to truly understand the
mechanisms of the disease and how therapies ideally should work."
Genizon has identified additional genes that complement the genes in the
PNAS article. These and their interactions are also under study for the
development of novel treatments for Crohn's disease.
About Genizon BioSciences
Genizon BioSciences Inc., founded in 1999, is the only source for
GeneMaps--comprehensive maps of genes, genetic markers, biochemical pathways
and drug targets that are unequivocally involved in causing human
disease-accelerating the development of safer, more effective medicines.
GeneMaps also lead to the development of predictive diagnostics that
facilitate personalized medicine. Genizon's proprietary, automated gene
discovery platform using genome-wide association studies involving thousands
of members of the Quebec Founder Population provides unprecedented
understanding of the genetic origins and mechanisms of common diseases,
resulting in the best possible drug targets and genetic markers. The company's
GeneMaps provide pharmaceutical partners with intellectual property that
creates opportunities for leadership in many therapeutic areas by bringing to
market better treatments that address the root causes of diseases. Genizon is
conducting gene discovery programs in more than 25 common diseases. Genizon
also provides high throughput, high quality SNP genotyping, genetic analysis,
gene expression and pharmacogenomics services to academic institutions,
research organizations and the biopharmaceutical industry.
For further information:
For further information: Genizon BioSciences Inc. Caroline Fortier,
514-708-4417 Vice President, Corporate Development
firstname.lastname@example.org or Schwartz Communications Lauren Arnold/Wendy
Mejia, 781-684-0770 email@example.com or Professor Stefan Schreiber,
+49-431-597-2350 Institute for Clinical Molecular Biology University Hospital
Schleswig-Holstein Schittenhelmstrasse 12 24105 Kiel, Germany Fax: